首页 > 最新文献

Best practice & research. Clinical endocrinology & metabolism最新文献

英文 中文
SDH-related head and neck paragangliomas: Unraveling PET radiomics beyond 18F-FDG 与 SDH 相关的头颈部副神经节瘤:揭示 18F-FDG 以外的 PET 放射组学。
IF 6.1 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-01 DOI: 10.1016/j.beem.2024.101926
Alessio Imperiale (Nuclear Medicine Physician) , Valentina Berti (Nuclear Medicine Physician)
Radiomics revolutionizes medical imaging by providing quantitative analysis that complements traditional qualitative assessments through advanced computational techniques. In this narrative review we have investigated the impact of succinate dehydrogenase (SDH) pathogenic variants on the radiomic profile of 18F-FDG, 18F-DOPA, and 68Ga-DOTA-peptides PET in paragangliomas, focusing on head and neck localizations (HNPGLs). This influence manifests in uptake intensity and textural heterogeneity, revealing a complex radiomic landscape that may reflect specific tumor behaviors and mutation statuses. By combining radiomic analysis with genetic data, we will gain new insights into the relationship between PET imaging features and underlying molecular changes. In the future, we envision an approach integrating macroscopic indices, such as lesion location, size, and SUV, with advanced computer-based algorithms. This comprehensive analysis could facilitate in vivo predictions of SDH pathogenic variants, thereby encouraging genetic testing, and ultimately improving patient outcomes.
放射组学通过先进的计算技术提供定量分析,补充了传统的定性评估,从而彻底改变了医学成像技术。在这篇叙述性综述中,我们研究了琥珀酸脱氢酶(SDH)致病变体对副神经节瘤18F-FDG、18F-DOPA和68Ga-DOTA-肽正电子发射计算机断层成像的放射组学特征的影响,重点是头颈部定位(HNPGL)。这种影响表现为摄取强度和纹理异质性,揭示了可能反映特定肿瘤行为和突变状态的复杂放射组学景观。通过将放射组学分析与基因数据相结合,我们将获得 PET 成像特征与潜在分子变化之间关系的新见解。未来,我们设想一种将病灶位置、大小和 SUV 等宏观指标与先进的计算机算法相结合的方法。这种综合分析有助于在体内预测 SDH 的致病变异,从而鼓励基因检测,最终改善患者的预后。
{"title":"SDH-related head and neck paragangliomas: Unraveling PET radiomics beyond 18F-FDG","authors":"Alessio Imperiale (Nuclear Medicine Physician) ,&nbsp;Valentina Berti (Nuclear Medicine Physician)","doi":"10.1016/j.beem.2024.101926","DOIUrl":"10.1016/j.beem.2024.101926","url":null,"abstract":"<div><div>Radiomics revolutionizes medical imaging by providing quantitative analysis that complements traditional qualitative assessments through advanced computational techniques. In this narrative review we have investigated the impact of succinate dehydrogenase (<em>SDH</em>) pathogenic variants on the radiomic profile of <sup>18</sup>F-FDG, <sup>18</sup>F-DOPA, and <sup>68</sup>Ga-DOTA-peptides PET in paragangliomas, focusing on head and neck localizations (HNPGLs). This influence manifests in uptake intensity and textural heterogeneity, revealing a complex radiomic landscape that may reflect specific tumor behaviors and mutation statuses. By combining radiomic analysis with genetic data, we will gain new insights into the relationship between PET imaging features and underlying molecular changes. In the future, we envision an approach integrating macroscopic indices, such as lesion location, size, and SUV, with advanced computer-based algorithms. This comprehensive analysis could facilitate <em>in vivo</em> predictions of <em>SDH</em> pathogenic variants, thereby encouraging genetic testing, and ultimately improving patient outcomes.</div></div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"39 1","pages":"Article 101926"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142082832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systemic therapy for patients with metastatic pheochromocytoma and paraganglioma
IF 6.1 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-01 DOI: 10.1016/j.beem.2025.101977
Alessa Fischer (Resident Internal Medicine and Endocrinology) , Jaydira del Rivero (Associate Research Physician) , Katharina Wang (Resident Internal Medicine and Endocrinology) , Svenja Nölting (Assistant Professor) , Camilo Jimenez (Professor)
Pheochromocytomas and paragangliomas are rare neuroendocrine tumors derived from the paraganglia. These tumors frequently secrete excessive amounts of catecholamines leading to cardiovascular and gastrointestinal complications. While all pheochromocytomas and paragangliomas possess the potential for metastasis, actual metastatic occurrences are observed in approximately one third of cases. The metastases primarily affect the lymph nodes, skeletal system, liver, and lungs. Furthermore, patients often experience a reduced overall survival rate attributed to factors such as tumor size, disease advancement, and excessive catecholamine secretion. For several decades, treatment options for patients diagnosed with metastatic pheochromocytomas and paragangliomas have primarily included combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine, along with Iodine-131-metaiodobenzylguanidine. However, significant advancements in scientific research over the past 25 years have enabled a comprehensive characterization of these tumors from biochemical, molecular, and diagnostic standpoints, resulting in the identification of new therapeutic alternatives for affected patients. In the last decade, we have witnessed the introduction of innovative systemic therapies specifically designed for those with metastatic pheochromocytomas and paragangliomas. In this review, we aim to present findings on the efficacy, safety, and overall activity from prospective clinical trials involving radiopharmaceuticals and tyrosine kinase inhibitors, and we will also outline the prospective advantages of additional novel therapies currently under evaluation.
{"title":"Systemic therapy for patients with metastatic pheochromocytoma and paraganglioma","authors":"Alessa Fischer (Resident Internal Medicine and Endocrinology) ,&nbsp;Jaydira del Rivero (Associate Research Physician) ,&nbsp;Katharina Wang (Resident Internal Medicine and Endocrinology) ,&nbsp;Svenja Nölting (Assistant Professor) ,&nbsp;Camilo Jimenez (Professor)","doi":"10.1016/j.beem.2025.101977","DOIUrl":"10.1016/j.beem.2025.101977","url":null,"abstract":"<div><div>Pheochromocytomas and paragangliomas are rare neuroendocrine tumors derived from the paraganglia. These tumors frequently secrete excessive amounts of catecholamines leading to cardiovascular and gastrointestinal complications. While all pheochromocytomas and paragangliomas possess the potential for metastasis, actual metastatic occurrences are observed in approximately one third of cases. The metastases primarily affect the lymph nodes, skeletal system, liver, and lungs. Furthermore, patients often experience a reduced overall survival rate attributed to factors such as tumor size, disease advancement, and excessive catecholamine secretion. For several decades, treatment options for patients diagnosed with metastatic pheochromocytomas and paragangliomas have primarily included combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine, along with Iodine-131-metaiodobenzylguanidine. However, significant advancements in scientific research over the past 25 years have enabled a comprehensive characterization of these tumors from biochemical, molecular, and diagnostic standpoints, resulting in the identification of new therapeutic alternatives for affected patients. In the last decade, we have witnessed the introduction of innovative systemic therapies specifically designed for those with metastatic pheochromocytomas and paragangliomas. In this review, we aim to present findings on the efficacy, safety, and overall activity from prospective clinical trials involving radiopharmaceuticals and tyrosine kinase inhibitors, and we will also outline the prospective advantages of additional novel therapies currently under evaluation.</div></div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"39 1","pages":"Article 101977"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143070222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overview of recent guidelines and consensus statements on initial screening and management of phaeochromocytoma and paraganglioma in SDHx pathogenic variant carriers and patients 关于 SDHx 致病变异携带者和患者中的嗜铬细胞瘤和副神经节瘤的初步筛查和管理的最新指南和共识声明概览
IF 6.1 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-01 DOI: 10.1016/j.beem.2024.101938
Charlotte Lussey-Lepoutre , Karel Pacak , Ashley Grossman , David Taieb , Laurence Amar
Phaeochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumours with a strong genetic predisposition, involving over 20 genes and with germline pathogenic variants identified in 40 % of cases. The succinate dehydrogenase (SDHx) genes are the most commonly implicated in hereditary PPGLs, accounting for 20 % of cases, and present unique diagnostic and treatment challenges due to their potential for multiple, recurrent, and aggressive manifestations, often necessitating lifelong follow-up. Over the past two decades, advances in biochemical and imaging assessments, management, and follow-up protocols have significantly improved care for both adult and paediatric patients. These advances include next-generation sequencing, new biochemical tests, cluster-specific functional imaging, and improved surgical and radiotherapy techniques, such as stereotactic surgery and peptide receptor radionuclide therapy (PRRT). International consensus guidelines have been developed to standardise the management of patients with SDHx pathogenic variants, emphasising multidisciplinary approaches and frequent tumour board discussions. These guidelines, summarised below, cover recommendations for initial genetic testing, tumour screening, follow-up care, and management of patients and asymptomatic carriers.
辉铬细胞瘤和副神经节瘤(PPGLs)是一种罕见的神经内分泌肿瘤,具有很强的遗传倾向,涉及 20 多个基因,40% 的病例中发现了种系致病变体。琥珀酸脱氢酶()基因是遗传性 PPGLs 最常涉及的基因,占病例的 20%,由于其潜在的多发性、复发性和侵袭性表现,给诊断和治疗带来了独特的挑战,往往需要终生随访。在过去二十年中,生化和影像评估、管理和随访方案的进步大大改善了对成人和儿童患者的治疗。这些进步包括下一代测序、新的生化检验、集群特异性功能成像以及改进的手术和放疗技术,如立体定向手术和肽受体放射性核素治疗(PRRT)。目前已制定了国际共识指南,以规范对致病变异患者的管理,强调多学科方法和经常性的肿瘤委员会讨论。这些指南涵盖了对初始基因检测、肿瘤筛查、后续治疗以及患者和无症状携带者管理的建议,概述如下。
{"title":"Overview of recent guidelines and consensus statements on initial screening and management of phaeochromocytoma and paraganglioma in SDHx pathogenic variant carriers and patients","authors":"Charlotte Lussey-Lepoutre ,&nbsp;Karel Pacak ,&nbsp;Ashley Grossman ,&nbsp;David Taieb ,&nbsp;Laurence Amar","doi":"10.1016/j.beem.2024.101938","DOIUrl":"10.1016/j.beem.2024.101938","url":null,"abstract":"<div><div>Phaeochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumours with a strong genetic predisposition, involving over 20 genes and with germline pathogenic variants identified in 40 % of cases. The succinate dehydrogenase (<em>SDHx</em>) genes are the most commonly implicated in hereditary PPGLs, accounting for 20 % of cases, and present unique diagnostic and treatment challenges due to their potential for multiple, recurrent, and aggressive manifestations, often necessitating lifelong follow-up. Over the past two decades, advances in biochemical and imaging assessments, management, and follow-up protocols have significantly improved care for both adult and paediatric patients. These advances include next-generation sequencing, new biochemical tests, cluster-specific functional imaging, and improved surgical and radiotherapy techniques, such as stereotactic surgery and peptide receptor radionuclide therapy (PRRT). International consensus guidelines have been developed to standardise the management of patients with <em>SDHx</em> pathogenic variants, emphasising multidisciplinary approaches and frequent tumour board discussions. These guidelines, summarised below, cover recommendations for initial genetic testing, tumour screening, follow-up care, and management of patients and asymptomatic carriers.</div></div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"39 1","pages":"Article 101938"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142267231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Progress in surgical approaches and outcomes of patients with pheochromocytoma and paraganglioma 嗜铬细胞瘤和副神经节瘤患者的手术方法和疗效进展。
IF 6.1 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-01 DOI: 10.1016/j.beem.2024.101954
Lindsay R. Friedman (Surgical Oncology Research Fellow), Bhavishya Ramamoorthy (Surgical Oncology Research Fellow), Naris Nilubol (Endocrine Surgeon)
Significant advances have been made in the past few decades in surgical management and outcomes of patients with pheochromocytoma and paraganglioma. Improvements in preoperative hypertensive control with the implementation of alpha- and beta-adrenergic blockade has resulted in better intra-operative blood pressure control and less incidence of hypertensive crises, which had been a large source of morbidity in the past. Emphasis on anesthesia and surgical team communication has also assisted in minimizing intraoperative hypertensive events at critical points of the operation. Shifting away from open resection, the now standard-of-care laparoscopic and minimally invasive adrenalectomy offers less pain, shorter hospitalizations, and quicker recoveries. Patient underlying germline mutations can guide the timing, approach, and extent of surgery. Postoperative outcomes have significantly improved with recent advancements in perioperative care in addition to regimented biochemical and radiographic surveillance. Here, we highlight the recent advancements in surgical approaches and outcomes for patients with pheochromocytoma and paraganglioma.
过去几十年来,嗜铬细胞瘤和副神经节瘤患者的手术治疗和疗效取得了重大进展。随着α-和β-肾上腺素能阻滞剂的应用,术前高血压控制得到了改善,术中血压得到了更好的控制,高血压危象的发生率也降低了,而这在过去一直是发病率的主要来源。重视麻醉和手术团队的沟通也有助于在手术的关键时刻将术中高血压事件降至最低。现在,腹腔镜和微创肾上腺切除术已不再是开腹切除术,而是标准的微创手术,疼痛更轻、住院时间更短、恢复更快。患者潜在的基因突变可以指导手术的时机、方法和范围。除了规范的生化和影像学监测外,围手术期护理的最新进展也大大改善了术后效果。在此,我们将重点介绍嗜铬细胞瘤和副神经节瘤患者手术方法和疗效的最新进展。
{"title":"Progress in surgical approaches and outcomes of patients with pheochromocytoma and paraganglioma","authors":"Lindsay R. Friedman (Surgical Oncology Research Fellow),&nbsp;Bhavishya Ramamoorthy (Surgical Oncology Research Fellow),&nbsp;Naris Nilubol (Endocrine Surgeon)","doi":"10.1016/j.beem.2024.101954","DOIUrl":"10.1016/j.beem.2024.101954","url":null,"abstract":"<div><div>Significant advances have been made in the past few decades in surgical management and outcomes of patients with pheochromocytoma and paraganglioma. Improvements in preoperative hypertensive control with the implementation of alpha- and beta-adrenergic blockade has resulted in better intra-operative blood pressure control and less incidence of hypertensive crises, which had been a large source of morbidity in the past. Emphasis on anesthesia and surgical team communication has also assisted in minimizing intraoperative hypertensive events at critical points of the operation. Shifting away from open resection, the now standard-of-care laparoscopic and minimally invasive adrenalectomy offers less pain, shorter hospitalizations, and quicker recoveries. Patient underlying germline mutations can guide the timing, approach, and extent of surgery. Postoperative outcomes have significantly improved with recent advancements in perioperative care in addition to regimented biochemical and radiographic surveillance. Here, we highlight the recent advancements in surgical approaches and outcomes for patients with pheochromocytoma and paraganglioma.</div></div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"39 1","pages":"Article 101954"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142376433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Best practice and research clinical endocrinology and metabolism issue on phaeochromocytomas and paragangliomas
IF 6.1 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-01 DOI: 10.1016/j.beem.2025.101976
Karel Pacak , Svenja Nölting
{"title":"Best practice and research clinical endocrinology and metabolism issue on phaeochromocytomas and paragangliomas","authors":"Karel Pacak ,&nbsp;Svenja Nölting","doi":"10.1016/j.beem.2025.101976","DOIUrl":"10.1016/j.beem.2025.101976","url":null,"abstract":"","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"39 1","pages":"Article 101976"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143070221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Personalized management for phaeochromocytomas and paragangliomas in Latin America: A genetic perspective 拉丁美洲嗜铬细胞瘤和副神经节瘤的个性化治疗:遗传学视角。
IF 6.1 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-01 DOI: 10.1016/j.beem.2024.101922
Felipe Freitas-Castro (Postdoctoral Fellow) , Madson Q. Almeida (Associate Professor)
Phaeochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors with clinical heterogeneity and a high association with hereditary disease, affecting approximately 30 % of the cases. Differences in the presentation and genetic etiologies of PPGLs have been demonstrated between Chinese and European patients. The frequency of germline genetic diagnosis was remarkably higher in Brazilian patients (∼50 %) compared with other cohorts (Chinese 21 %, European 31 %, and The Cancer Genome Atlas Program cohort 27 %). Interestingly, germline SDHB genetic defects were also more prevalent in Brazilian patients (17 %) with PPGLs when compared with other cohorts (3–9 %). The SDHB exon 1 deletion was responsible for approximately 50 % of the SDHB pathogenic/likely pathogenic variants in Brazilian patients with PPGLs due to a founder effect. The germline SDHB exon 1 deletion represents ∼10 % of the germline drivers in Brazilian patients (and possibly in Latin America). Therefore, a single diagnostic PCR for the SDHB exon 1 deletion might be very useful in clinical practice for genetic testing and counseling of patients with PPGLs in Latin America.
辉铬细胞瘤和副神经节瘤(PPGLs)是一种罕见的神经内分泌肿瘤,具有临床异质性,与遗传性疾病高度相关,约占病例的 30%。中国和欧洲患者在 PPGLs 的表现和遗传病因方面存在差异。与其他队列(中国 21%、欧洲 31% 和癌症基因组图谱计划队列 27%)相比,巴西患者的种系遗传诊断频率明显更高(50%)。有趣的是,与其他队列(3%-9%)相比,种系SDHB基因缺陷在巴西PPGL患者(17%)中也更为普遍。在巴西PPGLs患者中,SDHB外显子1缺失导致的SDHB致病/可能致病变异约占50%,这是由于创始效应所致。种系 SDHB 外显子 1 缺失占巴西(可能也包括拉丁美洲)患者种系驱动因子的 10%。因此,SDHB 1 号外显子缺失的单一诊断 PCR 可能对拉丁美洲 PPGL 患者的基因检测和咨询临床实践非常有用。
{"title":"Personalized management for phaeochromocytomas and paragangliomas in Latin America: A genetic perspective","authors":"Felipe Freitas-Castro (Postdoctoral Fellow) ,&nbsp;Madson Q. Almeida (Associate Professor)","doi":"10.1016/j.beem.2024.101922","DOIUrl":"10.1016/j.beem.2024.101922","url":null,"abstract":"<div><div>Phaeochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors with clinical heterogeneity and a high association with hereditary disease, affecting approximately 30 % of the cases. Differences in the presentation and genetic etiologies of PPGLs have been demonstrated between Chinese and European patients. The frequency of germline genetic diagnosis was remarkably higher in Brazilian patients (∼50 %) compared with other cohorts (Chinese 21 %, European 31 %, and The Cancer Genome Atlas Program cohort 27 %). Interestingly, germline <em>SDHB</em> genetic defects were also more prevalent in Brazilian patients (17 %) with PPGLs when compared with other cohorts (3–9 %). The <em>SDHB</em> exon 1 deletion was responsible for approximately 50 % of the <em>SDHB</em> pathogenic/likely pathogenic variants in Brazilian patients with PPGLs due to a founder effect. The germline <em>SDHB</em> exon 1 deletion represents ∼10 % of the germline drivers in Brazilian patients (and possibly in Latin America). Therefore, a single diagnostic PCR for the <em>SDHB</em> exon 1 deletion might be very useful in clinical practice for genetic testing and counseling of patients with PPGLs in Latin America.</div></div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"39 1","pages":"Article 101922"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142147066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of B cells in intratumoral MBTA immunotherapy of murine pheochromocytoma model B 细胞在小鼠嗜铬细胞瘤模型瘤内 MBTA 免疫疗法中的作用
IF 6.1 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-01 DOI: 10.1016/j.beem.2024.101941
Ondrej Uher (Postdoctoral Fellow) , Katerina Hadrava Vanova (Postdoctoral Fellow) , Katerina Petrlakova (PhD Candidate) , Rachael Labitt (Attending Veterinarian) , Radka Lencova (PhD Candidate) , Andrea Frejlachova (PhD Candidate) , Juan Ye (Postdoctoral Fellow) , Herui Wang (Staff Scientist) , Michal Masarik (Senior Investigator) , Jan Zenka (Senior Investigator) , Zhengping Zhuang (Senior Investigator) , Karel Pacak (Senior Investigator)
Immunotherapy represents a revolutionary advancement in cancer treatment, which has traditionally focused on T cells; however, the role of B cells in cancer immunotherapy has gained interest because of their role in antigen presentation, antibody production, and cytokine release. In this study, we examined the role of B cells in previously developed intratumoral MBTA therapy (mannan-BAM, TLR ligands, and anti-CD40 antibody) in murine models of MTT pheochromocytoma. The results indicated that B cells significantly enhance the success of MBTA therapy, with wild-type mice exhibiting a lower tumor incidence and smaller tumors compared with B cell-deficient mice. Increased IL-6 and TNF-alpha levels indicated severe inflammation and a potential cytokine storm in B cell-deficient mice. Neutralization of TNF-alpha ameliorated these complications but resulted in increased tumor recurrence. The results highlight the important role of B cells in enhancing the immune response and maintaining immune homeostasis during MBTA therapy. Our findings offer new insights into improving therapeutic outcomes.
免疫疗法代表了癌症治疗的革命性进步,传统的癌症治疗主要集中在 T 细胞上;然而,由于 B 细胞在抗原呈递、抗体产生和细胞因子释放中的作用,它们在癌症免疫疗法中的作用也受到了关注。在本研究中,我们在 MTT 嗜铬细胞瘤小鼠模型中研究了 B 细胞在先前开发的瘤内 MBTA 疗法(甘露聚糖-BAM、TLR 配体和抗 CD40 抗体)中的作用。结果表明,B细胞能显著提高MBTA疗法的成功率,与B细胞缺陷小鼠相比,野生型小鼠的肿瘤发病率更低,肿瘤更小。IL-6和TNF-α水平升高表明B细胞缺陷小鼠存在严重的炎症和潜在的细胞因子风暴。中和 TNF-α 可改善这些并发症,但会导致肿瘤复发。这些结果突显了 B 细胞在 MBTA 治疗过程中增强免疫反应和维持免疫平衡的重要作用。我们的研究结果为改善治疗效果提供了新的见解。
{"title":"Role of B cells in intratumoral MBTA immunotherapy of murine pheochromocytoma model","authors":"Ondrej Uher (Postdoctoral Fellow) ,&nbsp;Katerina Hadrava Vanova (Postdoctoral Fellow) ,&nbsp;Katerina Petrlakova (PhD Candidate) ,&nbsp;Rachael Labitt (Attending Veterinarian) ,&nbsp;Radka Lencova (PhD Candidate) ,&nbsp;Andrea Frejlachova (PhD Candidate) ,&nbsp;Juan Ye (Postdoctoral Fellow) ,&nbsp;Herui Wang (Staff Scientist) ,&nbsp;Michal Masarik (Senior Investigator) ,&nbsp;Jan Zenka (Senior Investigator) ,&nbsp;Zhengping Zhuang (Senior Investigator) ,&nbsp;Karel Pacak (Senior Investigator)","doi":"10.1016/j.beem.2024.101941","DOIUrl":"10.1016/j.beem.2024.101941","url":null,"abstract":"<div><div>Immunotherapy represents a revolutionary advancement in cancer treatment, which has traditionally focused on T cells; however, the role of B cells in cancer immunotherapy has gained interest because of their role in antigen presentation, antibody production, and cytokine release. In this study, we examined the role of B cells in previously developed intratumoral MBTA therapy (mannan-BAM, TLR ligands, and anti-CD40 antibody) in murine models of MTT pheochromocytoma. The results indicated that B cells significantly enhance the success of MBTA therapy, with wild-type mice exhibiting a lower tumor incidence and smaller tumors compared with B cell-deficient mice. Increased IL-6 and TNF-alpha levels indicated severe inflammation and a potential cytokine storm in B cell-deficient mice. Neutralization of TNF-alpha ameliorated these complications but resulted in increased tumor recurrence. The results highlight the important role of B cells in enhancing the immune response and maintaining immune homeostasis during MBTA therapy. Our findings offer new insights into improving therapeutic outcomes.</div></div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"39 1","pages":"Article 101941"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142267228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current views on paediatric phaeochromocytoma and paraganglioma with a focus on newest guidelines 当前对儿科嗜铬细胞瘤和副神经节瘤的看法,重点是最新指南。
IF 6.1 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-01 DOI: 10.1016/j.beem.2024.101957
Christina Pamporaki (Endocrinologist) , Ruth T. Casey (Endocrinologist)
Phaeochromocytoma and paraganglioma (PPGL) are rare neuroendocrine tumours which arise from chromaffin cells of the adrenal medulla or extra-adrenal autonomic ganglia. PPGL most commonly present in adulthood but can arise in childhood and adolescence with an estimated annual incidence of 0.5 cases per million children per year. There have been significant advances in the diagnosis and management of PPGL over the past 2–3 decades based largely on the study of adult patients. These advances in clinical knowledge can be applied to paediatric patients but like other cancers, paediatric PPGL must be viewed as a distinct subset with their own specific challenges and opportunities for improved clinical care. This review article provides an overview on the diagnosis and management of PPGL in children focusing on recent international guidance.
绒毛膜细胞瘤和副神经节瘤(PPGL)是一种罕见的神经内分泌肿瘤,源于肾上腺髓质或肾上腺外自主神经节的绒毛膜细胞。PPGL 最常见于成年期,但也可发生在儿童和青少年时期,估计每年的发病率为每百万儿童中 0.5 例。在过去的二三十年里,主要基于对成年患者的研究,PPGL 的诊断和治疗取得了重大进展。这些临床知识的进步可以应用于儿科患者,但与其他癌症一样,儿科PPGL必须被视为一个独特的子集,在改善临床护理方面有其自身的特殊挑战和机遇。这篇综述文章概述了儿童 PPGL 的诊断和管理,重点是最新的国际指南。
{"title":"Current views on paediatric phaeochromocytoma and paraganglioma with a focus on newest guidelines","authors":"Christina Pamporaki (Endocrinologist) ,&nbsp;Ruth T. Casey (Endocrinologist)","doi":"10.1016/j.beem.2024.101957","DOIUrl":"10.1016/j.beem.2024.101957","url":null,"abstract":"<div><div>Phaeochromocytoma and paraganglioma (PPGL) are rare neuroendocrine tumours which arise from chromaffin cells of the adrenal medulla or extra-adrenal autonomic ganglia. PPGL most commonly present in adulthood but can arise in childhood and adolescence with an estimated annual incidence of 0.5 cases per million children per year. There have been significant advances in the diagnosis and management of PPGL over the past 2–3 decades based largely on the study of adult patients. These advances in clinical knowledge can be applied to paediatric patients but like other cancers, paediatric PPGL must be viewed as a distinct subset with their own specific challenges and opportunities for improved clinical care. This review article provides an overview on the diagnosis and management of PPGL in children focusing on recent international guidance.</div></div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"39 1","pages":"Article 101957"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142649974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The current and upcoming era of radiomics in phaeochromocytoma and paraganglioma phaeochromocytoma 和副神经节瘤放射组学的当前和未来时代。
IF 6.1 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-01 DOI: 10.1016/j.beem.2024.101923
Zbyněk Tüdös (Associate Professor in Radiology) , Lucia Veverková (Consultant in Radiology) , Jan Baxa (Professor in Radiology) , Igor Hartmann (Consultant in Urology) , Filip Čtvrtlík (Associate Professor in Radiology)
The topic of the diagnosis of phaeochromocytomas remains highly relevant because of advances in laboratory diagnostics, genetics, and therapeutic options and also the development of imaging methods. Computed tomography still represents an essential tool in clinical practice, especially in incidentally discovered adrenal masses; it allows morphological evaluation, including size, shape, necrosis, and unenhanced attenuation. More advanced post-processing tools to analyse digital images, such as texture analysis and radiomics, are currently being studied. Radiomic features utilise digital image pixels to calculate parameters and relations undetectable by the human eye. On the other hand, the amount of radiomic data requires massive computer capacity. Radiomics, together with machine learning and artificial intelligence in general, has the potential to improve not only the differential diagnosis but also the prediction of complications and therapy outcomes of phaeochromocytomas in the future. Currently, the potential of radiomics and machine learning does not match expectations and awaits its fulfilment.
由于实验室诊断、遗传学和治疗方法的进步,以及成像方法的发展,有关肾上腺绒毛膜细胞瘤诊断的话题仍然具有很强的现实意义。计算机断层扫描仍然是临床实践中必不可少的工具,尤其是在偶然发现肾上腺肿块时;它可以进行形态学评估,包括大小、形状、坏死和未增强衰减。目前正在研究更先进的后处理工具来分析数字图像,如纹理分析和放射组学。放射组学特征利用数字图像像素计算人眼无法检测的参数和关系。另一方面,大量的辐射组学数据需要庞大的计算机容量。放射组学与机器学习和人工智能一起,不仅有可能改善鉴别诊断,还能在未来预测辉细胞瘤的并发症和治疗效果。目前,放射组学和机器学习的潜力尚未达到预期,有待发挥。
{"title":"The current and upcoming era of radiomics in phaeochromocytoma and paraganglioma","authors":"Zbyněk Tüdös (Associate Professor in Radiology) ,&nbsp;Lucia Veverková (Consultant in Radiology) ,&nbsp;Jan Baxa (Professor in Radiology) ,&nbsp;Igor Hartmann (Consultant in Urology) ,&nbsp;Filip Čtvrtlík (Associate Professor in Radiology)","doi":"10.1016/j.beem.2024.101923","DOIUrl":"10.1016/j.beem.2024.101923","url":null,"abstract":"<div><div>The topic of the diagnosis of phaeochromocytomas remains highly relevant because of advances in laboratory diagnostics, genetics, and therapeutic options and also the development of imaging methods. Computed tomography still represents an essential tool in clinical practice, especially in incidentally discovered adrenal masses; it allows morphological evaluation, including size, shape, necrosis, and unenhanced attenuation. More advanced post-processing tools to analyse digital images, such as texture analysis and radiomics, are currently being studied. Radiomic features utilise digital image pixels to calculate parameters and relations undetectable by the human eye. On the other hand, the amount of radiomic data requires massive computer capacity. Radiomics, together with machine learning and artificial intelligence in general, has the potential to improve not only the differential diagnosis but also the prediction of complications and therapy outcomes of phaeochromocytomas in the future. Currently, the potential of radiomics and machine learning does not match expectations and awaits its fulfilment.</div></div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"39 1","pages":"Article 101923"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent progress in molecular classification of phaeochromocytoma and paraganglioma 嗜铬细胞瘤和副神经节瘤分子分类的最新进展
IF 6.1 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-12-01 DOI: 10.1016/j.beem.2024.101939
Emma Boehm , Anthony J. Gill , Roderick Clifton-Bligh , Richard W. Tothill
Phaeochromocytomas (PC) and paragangliomas (PG) are neural crest cancers with high heritability. Recent advances in molecular profiling, including multi-omics and single cell genomics has identified up to seven distinct molecular subtypes. These subtypes are defined by mutations involving hypoxia-inducible factors (HIFs), Krebs cycle, kinase and WNT signalling, but are also defined by chromaffin differentiation states. PCPG have a dominant proangiogenic microenvironment linked to HIF pathway activity and are generally considered “immune cold” tumours with a high number of macrophages. PCPG subtypes can indicate increased metastatic risk but secondary mutations in telomere maintenance genes TERT or ATRX are required to drive the metastatic phenotype. Molecular profiling can identify molecular therapeutic (e.g. RET and EPAS1) and radiopharmaceutical targets while also helping to support variant pathogenicity and familial risk. Molecular profiling and subtyping of PCPG therefore confers the possibility of nuanced prognostication and individual treatment stratification but this still requires large-scale prospective validation.
辉色素细胞瘤(PC)和副神经节瘤(PG)是具有高度遗传性的神经嵴癌症。分子图谱分析(包括多组学和单细胞基因组学)的最新进展确定了多达七种不同的分子亚型。这些亚型由涉及缺氧诱导因子(HIFs)、克雷布斯循环、激酶和 WNT 信号的突变所定义,但也由嗜铬细胞分化状态所定义。PCPG 具有与 HIF 通路活性相关的主要促血管生成微环境,通常被认为是具有大量巨噬细胞的 "免疫冷 "肿瘤。PCPG 亚型可表明转移风险增加,但端粒维持基因的继发性突变或需要驱动转移表型。分子图谱分析可确定分子治疗(如和)和放射性药物靶点,同时也有助于支持变异致病性和家族风险。因此,PCPG 的分子图谱分析和亚型鉴定为细微的预后判断和个体治疗分层提供了可能,但这仍需要大规模的前瞻性验证。
{"title":"Recent progress in molecular classification of phaeochromocytoma and paraganglioma","authors":"Emma Boehm ,&nbsp;Anthony J. Gill ,&nbsp;Roderick Clifton-Bligh ,&nbsp;Richard W. Tothill","doi":"10.1016/j.beem.2024.101939","DOIUrl":"10.1016/j.beem.2024.101939","url":null,"abstract":"<div><div>Phaeochromocytomas (PC) and paragangliomas (PG) are neural crest cancers with high heritability. Recent advances in molecular profiling, including multi-omics and single cell genomics has identified up to seven distinct molecular subtypes. These subtypes are defined by mutations involving hypoxia-inducible factors (HIFs), Krebs cycle, kinase and WNT signalling, but are also defined by chromaffin differentiation states. PCPG have a dominant proangiogenic microenvironment linked to HIF pathway activity and are generally considered “immune cold” tumours with a high number of macrophages. PCPG subtypes can indicate increased metastatic risk but secondary mutations in telomere maintenance genes <em>TERT</em> or <em>ATRX</em> are required to drive the metastatic phenotype. Molecular profiling can identify molecular therapeutic (e.g. <em>RET</em> and <em>EPAS1</em>) and radiopharmaceutical targets while also helping to support variant pathogenicity and familial risk. Molecular profiling and subtyping of PCPG therefore confers the possibility of nuanced prognostication and individual treatment stratification but this still requires large-scale prospective validation.</div></div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"38 6","pages":"Article 101939"},"PeriodicalIF":6.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142267230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Best practice & research. Clinical endocrinology & metabolism
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1